← Compound index
COMPOUND RECORD / CAMPHANE-CHLOROBENZAMIDE

Camphane chlorobenzamideКамфановый хлорбензамид

An experimental chlorobenzamide designed as a structural analogue of Chlodantane. It has a camphane cage in place of Chlodantane’s adamantane cage.

Performance
Source linked

What the studies found

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

Study of multiple preparations

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Study notes · methods, sources and limitations

Participants or model Mouse pharmacology experiments

Important limitations

  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety. An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose. The Russian and English versions are one publication, not independent replication.

Pharmaceutical Chemistry Journal. 57(4):523–534 · Publication record

Original source or citation ↗

Study results and tables ↗

Laboratory analysis · 2019

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

Study of multiple preparations

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Study notes · methods, sources and limitations

Participants or model Chemical synthesis and characterization; background pharmacology citations

Important limitations

  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy. ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Russian Journal of General Chemistry. 89(3):399–404 · Publication record

Original source or citation ↗

Study results and tables ↗

Laboratory analysis · 2019

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

Study of multiple preparations

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Study notes · methods, sources and limitations

Participants or model Preclinical research; no human efficacy established

Important limitations

  • Chemistry and preclinical observations do not establish human efficacy or safety.

Zhurnal Organicheskoi Khimii. 55(11):1781–1788 · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Camphane chlorobenzamide

Names in this research collection

N-[(1R,2RS)-camphan-2-yl]-4-chlorobenzamide

Research background

An experimental camphane-based structural analogue of Chlodantane. The cage framework differs from adamantane; this is a chemical candidate, not an established treatment.

Compound class
Experimental adamantane / analogue
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Human efficacy results unavailable

Study methods

Source-specific animal, chemistry, patent or dissertation evidence

Independent replication

Independent replication not established; translations are not separate experiments

Source access

Access and review depth appear with each linked record

Safety evidence

Human safety and interactions not established; animal activity is not a safe-use recommendation

Open a topic for the evidence assessment.

More findings, background and history

Chlodantane, Cyclontane and the ADK research program ↗

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2023

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Study notes and original source
2023Animal / experimentalFull text available

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Population / setting
Mouse pharmacology experiments
Source reviewed
Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
  • An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
  • The Russian and English versions are one publication, not independent replication.

Reviewed 2026-10-03.

Read the source ↗

Laboratory analysis · 2019

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Study notes and original source
2019Analytical / composition studyFull text available

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Population / setting
Chemical synthesis and characterization; background pharmacology citations
Source reviewed
Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
  • ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Reviewed 2026-10-03.

Read the source ↗

Laboratory analysis · 2019

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Study notes and original source
2019Analytical / composition studyRussian-language source

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

· Zhurnal Organicheskoi Khimii. 55(11):1781–1788

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗